Bozitinib
6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
Molecular Identity
Bozitinib
6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
PubChem CID: 72202701
2D Structure
Properties
C20H15F3N8
Molecular Formula
424.40
Molecular Weight
g/mol
424.1372
Exact Mass
Da
2.1
XLogP
Drug-like (Lipinski: < 5)
78.7
TPSA
Good oral absorption (< 140 A²)
0
H-Bond Donors
8
H-Bond Acceptors
681
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
BozitinibVebreltinibPLB-1001APL-101Vebreltinib [USAN]2WZP8A9VFNCBI-31036-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazineCBT-101VEBRELTINIB [INN]VEBRELTINIB [WHO-DD]PLB1001Vebreltinib (USAN)6-(1-cyclopropylpyrazol-4-yl)-3-(difluoro-(6-fluoro-2-methylindazol-5-yl)methyl)-(1,2,4)triazolo(4,3-b)pyridazineRefChem:193883
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to Bozitinib
Loading drug network...